About 34,404 results
Bladder Cancer

Jul 28th, 2019 - "Whether you (or a loved one) are worried about developing bladder cancer, have just been diagnosed, are going through treatment, or are trying to stay well after treatment, this detailed guide can help you find the answers you need.

FDA grants orphan drug designation to Imfinzi for small cell lung cancer

Jul 11th, 2019 - The FDA granted orphan drug designation to durvalumab for the treatment of small cell lung cancer. Durvalumab (Imfinzi, AstraZeneca) — a human monoclonal antibody that binds to PD-L1 — already is approved in the United States for treatment of patients with unresectable, stage III non-small cell lung cancer who underwent chemotherapy and radiation. The agent also is approved for previously tr...

VENTANA PD-L1 (SP142) Assay - P160002/S009

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

Feb 14th, 2019 - The PD-1 inhibitor pembro has durable antitumor activity in pts with metastatic urothelial carcinoma. Upregulation of the PD-1 pathway has been observed in BCG-resistant NMIBC, suggesting pembro may benefit. Efficacy and safety of pembro in pts with HR, BCG-unresponsive NMIBC was evaluated in the single-arm phase 2 KEYNOTE-057 study; updated results for pts with carcinoma in situ (CIS) with or ...

A Retrospective Study of Patients Undergoing Radical Cystectomy and Receiving Peri-Operative Naloxegol or Alvimopan: Comparison of Length of Stay

Oct 11th, 2018 - Alvimopan is a μ-opioid receptor antagonist used in the post-operative period to decrease rates of post-operative ileus (POI) following radical cystectomy (RC) and thereby shorten length of stay (LOS). Naloxegol is a much less expensive drug of the same class that has yet to be studied for prevention of POI in the peri-operative period. The purpose of the current study is to evaluate the differ...

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018
Flaig, T.

Aug 31st, 2018 - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder can.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Spiess, P.,et al

Sep 30th, 2017 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cance.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer
Sam S. Chang

Feb 28th, 2017 - This guideline addresses four areas related to the treatment of muscle-invasive bladder cancer that has not metastasized. It first discusses initial patient evaluation and counseling and then offers recommendations on treatment.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Sam S. Chang

Feb 28th, 2017 - Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUI Guideline provides a clinical framework for the management of muscle-invasive urothelial bladder cancer. Topics covered include patient evaluation and counseling, as well as an in-depth discussion of treatment options, including chemotherapy, cystectomy, urinary diversion, lymphadenectomy, and variou bladder preservi.

Updated durvalumab monotherapy data confirm results in urothelial bladder cancer

Feb 16th, 2017 - AstraZeneca and its global biologics research and development arm, MedImmune, today announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial cancer (UC). Updated results from the Phase I/II trial, presented at the 2017 ASCO Genitourinary Cancers Symposium, showed an objective response rate (ORR) of 20.4% in all evaluable patients (n...

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline
Sam S. Chang

Sep 30th, 2016 - The survival rate for the majority of patients with non-muscle invasive bladder cancer (NMIBC) is favorable, however, the rates of recurrence and progression to muscle-invasive bladder cancer (MIBC) are important surrogate endpoints for overall prognosis, as these are major determinants of long-term outcome. The recurrence and progression probability rates depend on several clinical and patholo.

Guidelines on muscle-invasive and metastatic bladder cancer
Matthew I. Milowsky

May 31st, 2016 - To endorse the European Association of Urology guideline on muscle-invasive (MIBC) and metastatic bladder cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.

Circumcision Policy Statement

Aug 30th, 2012 - Male circumcision is a common procedure, generally performed during the newborn period in the United States. In 2007, the American Academy of Pediatrics (AAP) formed a multidisciplinary task force of AAP members and other stakeholders to evaluate the recent evidence on male circumcision and update the Academy’s 1999 recommendations in this area. Evaluation of current evidence indicates that the...

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospec...
BMJ (Clinical Research Ed.); Korhonen P, Heintjes EM et. al.

Aug 17th, 2016 - To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. Retrospective cohort study using propensity score matched cohorts. Healthcare databases from Finland, the Netherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records on prescriptions, hospitals, general practitioners, cancer, and deaths. Pati...

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT...
The Lancet. Oncology; Sternberg CN, Skoneczna I et. al.

Dec 16th, 2014 - Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder. This intergroup, open-label, randomised, phase 3 trial recruited patients from hospitals acr...

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, a...
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Plimack ER, Hoffman-Censits JH et. al.

May 13th, 2014 - Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequently adopted in practice because of concerns regarding toxicity and delay to cystectomy. We hypothesized that three cycles of neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) would be safe, shorten the time to surgery, and yield simi...


See risks and benefits of BAVENCIO® (avelumab). Get HCP Info & learn how BAVENCIO may treat metastatic Merkel cell carcinoma & advanced urothelial cancer.


Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocytemacrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, ...

VALSTAR® (valrubicin) Sterile Solution for Intravesical Instillation

Learn about VALSTAR® (valrubicin), including safety and side effects, features and risks, and full prescribing information.

BALVERSA™ (erdafitinib)

Learn about BALVERSA™ (erdafitinib) which is now approved. Read the press release.